Table 1.
Neoadjuvant setting.
| Author | Period | Study | Tumor Stage (No of Patients) |
Median Age, Years | DFS | OS | Toxicity (G > 2) |
Median FU, Months |
|---|---|---|---|---|---|---|---|---|
| Beriwal [19] | 2002–2011 | Mo. | III: 23; IVa: 3 | 73.5 (37–89) | 3-y:65.9% | 3-y: 61.2% | 2.38% | 15 (3–111) |
| Gaudineau [20] | 2001–2010 | Mo. | III–IV: 22 | 74 (51–81) | - | 5.1 y | 22.7% | 2.3 years |
| Natesan [21] | 2004–2012 | Mo. | II–III–IV: 639 | 68 | - | 3-y: 57.1% | n.a. | 21.9 |
| Richman [22] | 2012–2019 | Mo. | II–III–IV: 24 | 68 (59–72) | 2-y: 55% | 2-y: 69% | 70.8% | 20 (7–36) |
| Moore [23] | 2005–2009 | Mu. | III–Iva: 71 | - | - | - | 74.6% | 24.8– |
Abbreviations: DFS: disease-free survival; G: grade; Mo: monocentric; Mu: multicentric; na: not available; OS: overall survival; y: year.